Holen Sie sich die Stockscreener-App
0.3476
2.33%
-0.0083
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Form 8K Heron Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Heron Therapeutics signs multi-product license agreement with Long Grove By Investing.com - Investing.com Nigeria
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00 - MarketBeat
Heron Therapeutics, Inc. (HRTX) Options Chain - Yahoo Finance
Heron Therapeutics stock awaits its next reported figures - AD HOC NEWS
Heron Therapeutics (AXD2) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX) - MarketBeat
HRTX - Finviz
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc. - marketbeat.com
Heron Therapeutics stock trades at penny level as biotech focuses on pain and oncology pipeline - ad-hoc-news.de
AXD2 Forecast — Price Target — Prediction for 2027 - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Heron Therapeutics Stock Short Interest Rises to 31.36% - Quiver Quantitative
Heron (HRTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark at the Close; Post-Earnings: The Market Price Advances 2.91% on the DayAnalyst Coverage Count - careplusvn.com
Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron (HRTX) Results Review: EPS Comes in Below Forecast on the Day; Price Reaction: Shares Move 4.13% Down in Latest TradingEarnings Turnaround - vinanet.vn
Heron Therapeutics Earnings Call: Growth Meets New Risks - TipRanks
Heron (HRTX) Watch: Records a 4.65% Increase to $0.31 at the Close; Key Range: the Session Ends Within the Reported Technical Boundaries in the Available RecordIV Contraction - vinanet.vn
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating - Moomoo
Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M - TradingView
HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings - MarketBeat
HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY - webull.com
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating - Moomoo
--HC Wainwright Downgrades Heron Therapeutics to Neutral From Buy - Yahoo Finance
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... - finance.yahoo.com
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates - AlphaStreet
Heron Therapeutics: Q2 Earnings Snapshot - AOL.com
Heron Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Heron Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo Finance
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast By Investing.com - Investing.com Canada
Heron Therapeutics Q2 Earnings Call Highlights - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
development in the article - Minichart
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results - MarketBeat
HERON THERAPEUTICS INC HERON TH (0J4V.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Heron Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook - TradingView
Heron Therapeutics Q2 Revenue Rises To $37.7 Million - Quiver Quantitative
Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling - TradingView
Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell - MarketBeat
HERON THERAPEUTICS Q2 2026 Earnings Preview: Recent $HRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Heron Therapeutics Inc expected to post earnings of 1 cent a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research - MarketBeat
Earnings Preview: HRTX to Report Financial Results Pre-market on August 10 - Moomoo
HRTX Q2'26 Earnings: revenue estimate is 42.19M USD - TradingView
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday - MarketBeat
Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX - TradingView
HRTX Q1 2026 Earnings: Wider-than-Expected Loss Signals Ongoing Cost PressureEPS Estimate Trend - vinanet.vn
Heron Therapeutics Inc Revenue Breakdown – BX:AXD2 - TradingView
Heron Therapeutics Inc (HRTX) Institutional Confidence - TradingKey
Heron Therapeutics to Report Second Quarter 2026 Financial Results on August 10 - Quiver Quantitative
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 - The Manila Times
Orbimed Advisors LLC Makes New Investment in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Inc (HRTX) Cash Flow - TradingKey
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):